Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is just one of many ways larger companies help biotech entrepreneurs

Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities

They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body's reaction to then, affinity & avidity, CMC, and 'bead-on-a-string' approaches that some have used lately. Finally, a discussion of what the future holds.

AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner

Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think about improving selectivity and sensitivity. Plus, how AI is changing the field, what it takes to be differentiated, and implications of new startups sharing less knowledge than has been traditionally done.

Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is just one of many ways larger companies help biotech entrepreneurs

Servier's 'Golden Ticket' gave Deck Bio a place to work from at LabCentral and access to Servier's experts for advice. Jack and Irene discuss the benefits of this kind of support to a smaller company, and other ways more established players nurture the biotech ecosystem in hubs like Kendall Square.

Precision for Medicine CMO Harpreet Singh and Repertoire Immune Medicines CMO Robert Andtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs

In a wide-ranging discussion, Dr. Singh and Dr. Andtbacka reflect on the success of the immunotherapy field and the cancer centers that helped develop the new medicines, career leaps to industry, dealing with the risks of biotech, talking to investors, and advice for other CMOs.

Two leaders from the Harvard Biotech Club talk about their experience in the club, its new podcast, The Pulse, and an upcoming career fair on September 19th

Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have already been guests). Plus, the September 19th career fair that traditionally draws 1,000 attendees and so far already has 17 companies participating this year.